Physician profile
Yolanda Bledsoe
NPI 1396855391
$2,342.51
in general payments reported to CMS, 2019-2025
24 companies · $95.48 in 2025
The $95.48 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $848 · 2020: $188 · 2021: $119 · 2022: $320 · 2023: $308 · 2024: $464 · 2025: $95.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $867 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $866.88 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $262.72 | 2019-2024 | |
| Astellas Pharma US INC | $248.53 | 2019-2020 | |
| Glaxosmithkline, LLC. | $247.17 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $208.49 | 2019-2025 | Otezla, Repatha, Evenity |
| Abbvie INC. | $195.73 | 2021-2024 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $142.94 | 2019-2024 | Lokelma, Farxiga |
| Medtronic, INC. | $137.78 | 2022-2025 | Intellis Adaptivestim, Inceptiv |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.05 | 2019-2022 | |
| Novo Nordisk INC | $132.86 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $101.17 | 2019-2024 | Mounjaro |
| Abbott Laboratories | $79.17 | 2022-2024 | Freestyle Libre 3 |
| Allergan, INC. | $68.99 | 2020 | |
| Novartis Pharmaceuticals Corporation | $67.87 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $59.83 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $54.05 | 2024-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $37.79 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $34.04 | 2024-2025 | Eliquis, Camzyos |
| Dexcom, INC. | $25.72 | 2022-2023 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $24.70 | 2022 | |
| Neurocrine Biosciences, INC. | $23.60 | 2024 | Ingrezza |
| Ironwood Pharmaceuticals, INC | $21.11 | 2024 | |
| Merck Sharp & Dohme LLC | $18.75 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.66 | 2024 | Xifaxan |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yolanda Bledsoe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.